RxDoctor Payments Data

Megan Pelc, PA

Physician Assistant · Richland, MINPI 1326326190

Payments from drug & device makers

$933in general payments, 2019–2025

Across 28 payments — averaging $33.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$239
  • Abbott$154
  • Pfizer$131
  • Boehringer Ingelheim$102
  • AstraZeneca$98
  • Amgen$72
  • plus $137 from 6 others

What the payments were for

  • Food & beverage$933100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$933 in reported general payments places this provider in the 70th percentile of 5,453 physician assistant providers in Michigan.

See all physician assistant providers in Michigan

Medicare billing

Part B allowed, 2024
$12,217
Medicare patients
69
Services billed
152

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide39$44,796
RybelsusSemaglutide19$41,423
EliquisApixaban26$25,622
TrulicityDulaglutide17$25,380
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$20,489
FarxigaDapagliflozin Propanediol15$17,648
Atorvastatin Calcium129$1,600
Rosuvastatin Calcium89$1,556
Levothyroxine Sodium94$1,201
Estradiol21$1,170
Metoprolol Succinate58$1,135
Albuterol Sulfate HfaAlbuterol Sulfate32$1,079
Celecoxib29$1,055
Estradiol (Twice Weekly)Estradiol11$1,028
Lisinopril111$947

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus$239$41,42319 claims
PfizerEliquis$131$25,62226 claims
GSKTrelegy Ellipta$14$20,48913 claims
AstraZenecaFarxiga$98$17,64815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 5,453 physician assistant providers in Michigan.

Other physician assistant in Richland

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →